The Law Firm of Wohl & Fruchter Has Filed a Complaint Against Amyris, Inc.

  The Law Firm of Wohl & Fruchter Has Filed a Complaint Against Amyris, Inc.

Business Wire

NEW YORK -- May 20, 2013

The law firm of Wohl & Fruchter LLP has filed a securities class action
against Amyris, Inc. ("Amyris") (NYSE: AMRS), and its President and CEO, John
G. Melo. The action, filed in the United States District Court for the
Northern District of California, is on behalf of purchasers of Amyris
securities between April 29, 2011 and February 8, 2012, inclusive (the "Class
Period"). The class action seeks relief for violations of Sections 10(b) and
20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated
thereunder, based on defendants’ false and misleading statements, and
omissions of material information during the Class Period concerning, among
other things, Amyris’ ability to produce Biofene in commercially meaningful
volumes.

If you are a shareholder who purchased AMRS securities during the Class
Period, you have until July 15, 2013 to ask the Court to appoint you as Lead
Plaintiff for the class. A copy of the complaint in the class action can be
obtained at: http://www.wohlfruchter.com/cases/amrs.

To discuss this action, please contact J. Elazar Fruchter at
jfruchter@wohlfruchter.com or call toll free 866.582.8140.

Amyris uses patented engineered microbes to convert plant-based sugars into
renewable chemicals, including a chemical trademarked as Biofene, which can be
used in the manufacture of transportation fuels.

On April 29, 2011, Amyris issued a press release confirming that it had
designed a facility that would allow it to commence sustained commercial
production of Biofene. In May 2011, and again in August 2011, Amyris
executives made further statements indicating that Amyris could produce
Biofene in commercial quantities.

However, on November 1, 2011, Amyris announced a slowdown in production of
Biofene. On this news, the next trading day, Amyris’ share price fell over 20%
from $19.36 per share to $15.47 per share.

On February 9, 2012, Amyris executives reported a further slowdown in Biofene
production, and stated that the company was no longer forecasting positive
cash flow from operations and would require additional equity financing. On
this news, Amyris shares fell an additional 28%.

About Wohl & Fruchter

Wohl & Fruchter LLP represents plaintiffs in litigation arising from fraud and
other fiduciary breaches by corporate managers, as well as other complex
litigation matters. Please visit our website, www.wohlfruchter.com, to learn
more about our Firm, or contact one of our partners.

This release may be deemed to constitute attorney advertising.

Contact:

Wohl & Fruchter LLP
J. Elazar Fruchter, 845-425-4658
Toll Free 866-582-8140
jfruchter@wohlfruchter.com
www.wohlfruchter.com
 
Press spacebar to pause and continue. Press esc to stop.